



A next generation precision oncology company

## OncoHost revolutionizes cancer care by mapping patient-tumor dynamics using proteomics and AI

Dear investors,

I am happy to share with you OncoHost’s 2021 H2 update. We’ve made substantial progress on all fronts, and we are getting ready to launch our first product in the US.

In the second half of 2021 our major focus was launch preparations. We are now raising another round of funding to support our commercial operations and ongoing product and pipeline development.

### Product:

PROphet’s first indication is going to be non-small cell lung cancer (NSCLC) the most common form of lung cancer. We recently ran another iteration of training and validation of our platform, and I am happy to report a successful validation. We’ve reached our pre-defined success criteria and “locked” the MVP version. We were able to reach the pre-defined accuracy level with one, pre-treatment, blood test! This means that our launched product will require only one blood test instead of two. That means that our launched product will be the “PROphet Baseline” that was previously part of our pipeline plans with launch date set to 2023 (see R&D section of the H1 2021 investor update sent in June).



### WHAT WE PROVIDE IN PART I OF THE PROPHET® REPORT ?

Based on blood sample taken before treatment we provide

Response probability

- 3 months
- 6 months
- 1 year

- Disease progression – stratification to prolonged or limited benefit populations in terms of
  - Overall survival
  - Progression free survival



We signed a binding LOI with SomaLogic, Inc. (SLGC). Somalogic will be our proteomic panel provider and CLIA lab set up partner. Fully executed agreement will be signed in Q1 2022. The project is supported by Somalogic’s senior leadership, technical teams are already working together, and senior leadership meeting is set to January.

### CLIA Laboratory:

We rented a Laboratory space in Cary, North Carolina. The space has all the required permits for a laboratory and minor renovations will commence in January. Full lab set up and CLIA certification are planned for Q2 2022.



**Team:**

We hired additional data scientist

Dr. Ben Yallin, PhD - Ben has a doctorate in theoretical physics and mathematics and relevant industry experience.

We are now hiring a US based general manager for OncoHost Inc.

We have a new scientific advisory board member:



Professor David Gandara, MD-Professor of Medicine Emeritus at the University of California Davis. Director, Thoracic Oncology Program and Senior Advisor to the Director of the Division of Hematology/Oncology at UC Davis Comprehensive Cancer Center (UCDCCC)

**Media coverage:**

- A. <https://www.docwirenews.com/gu-oncology-now/phenotypic-precision-medicine-gu-kh/dr-of-fer-sharon-ceo-oncohost-talks-the-potential-impact-of-precision-medicine-on-cancer-therapy/>
- B. <https://www.biocentury.com/article/640714/oncohost-personalizing-cancer-treatment-based-on-host-response?editionId=ckvn8tdmoj1ip0c66x4b3z78c>
- C. <https://www.forbes.com/sites/gilpress/2021/10/31/oncohosts-algorithms-predict-cancer-patients-response-to-treatments/?sh=485acb07749b>
- D. <https://www.everydayhealth.com/cancer/lung-cancer/new-directions-what-innovations-are-coming-down-the-pike-for-lung-cancer/>
- E. <http://www.mobilehealthtimes.com/oncohost-wins-frost-sullivan-2021-technology-innovation-leadership-award-for-excellence-in-best-practices/>
- F. <https://www.selectscience.net/industry-news/oncohost/nhs-opens-eight-uk-clinical-trial-sites-to-assess-cancer-patient-response-to-immunotherapy-in-collaboration-with-oncohost/?&artID=54935>

**Public announcements:**

- A. <https://finance.yahoo.com/news/oncohost-announces-collaboration-heidelberg-universitys-130000483.html>
- B. <https://finance.yahoo.com/news/oncohost-publishes-data-identifying-predictive-120000532.html>
- C. <https://finance.yahoo.com/news/oncohost-welcomes-uc-davis-professor-130000517.html>
- D. <https://finance.yahoo.com/news/oncohost-wins-frost-sullivan-2021-120000611.html>

**Awards and recognitions:**

The team's hard work paid off. OncoHost won several important awards in the last 6 months.

1. [2021 Frost & Sullivan](#) Technology Innovation Leadership Award for the European AI-Based precision [oncology](#) market.
2. Best abstract award in the ESMO 2021 Biomarkers category.
3. 2021 Health Tech awards Best use of Artificial Intelligence: PROphet® – OncoHost

**Summary:**

We continue our work and efforts focusing on commercial launch of our product. We make progress on all fronts, product, R&D, science and clinical, team development and marcom. As always, the team is committed and engaged, our clinical collaborators support the trial and patient participation.

We believe that it is up to us to build a product with the highest scientific standards and clear clinical value proposition. If we do commercial success will follow.

I'd like to thank you again for your support in our journey. On behalf of myself and the team, we are committed to continuing our hard work towards bringing PROphet to the market.

Sincerely,

Ofer